Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of...

Click to view original post